⚖️ Head-to-Head📊 Clinical Data✅ 2026 Updated

Cjc 1295 vs Sermorelin

Which Is Right for You? Complete Comparison (2026)

CJC-1295 vs sermorelin compared: potency, half-life, safety data, availability, and who should choose each GHRH analogue for GH peptide protocols.

Last reviewed: March 2026

Download on theApp Store

Get it onGoogle Play

Cjc 1295 vs Sermorelin: At a Glance

Cjc 1295

✓Modified GHRH(1-29) analogue — stimulates GH release at the pituitary
✓DAC version binds albumin, extending half-life to ~8 days
✓Non-DAC (Mod GRF 1-29) has half-life of ~30 minutes
✓Produces sustained GH and IGF-1 elevation
✓Often stacked with GHRPs (e.g., Ipamorelin) for synergistic effect

Sermorelin

✓Synthetic GHRH(1-29) — the bioactive fragment of natural GHRH
✓Stimulates natural pulsatile GH release from the pituitary
✓Previously FDA-approved (Geref) for pediatric GH deficiency
✓Does not cause GH desensitization with chronic use
✓Half-life approximately 10-20 minutes

Detailed Comparison

Feature	Cjc 1295	Sermorelin
Mechanism	Growth hormone releasing hormone analogue	Growth hormone releasing hormone analogue
Dosing	DAC: 2 mg/week SC; No-DAC: 100 mcg 2-3x daily	200-500 mcg SC daily at bedtime
Administration	Subcutaneous injection	Subcutaneous injection
Half-life	DAC: ~8 days; No-DAC: ~30 min	~10-20 minutes
FDA Status	Not FDA-approved — research peptide	Previously FDA-approved (discontinued commercially)
Key Trial	Teichman SL et al. JCEM 2006 — sustained GH/IGF-1 elevation	Prakash A et al. BioDrugs 1999 — clinical review
Side Effects	Flushing, headache, injection site reactions, water retention	Injection site reactions, flushing, headache — generally well-tolerated

Which Should You Choose?

CJC-1295 (with or without DAC) (growth hormone releasing hormone analogue) and Sermorelin (GRF 1-29) (growth hormone releasing hormone analogue) serve different clinical roles despite both being in the GHRH analogue space. CJC-1295 (with or without DAC) modified ghrh(1-29) analogue that stimulates pituitary gh secretion with extended half-life via drug affinity complex (dac) binding to albumin. Sermorelin (GRF 1-29) synthetic 29-amino-acid analogue of natural ghrh that stimulates physiological gh release from the pituitary.

Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.

Track Both in Shotlee

Shotlee supports tracking any medication or peptide. Compare your results across different protocols with clean dose logs and outcome data.

Making an Informed Choice Between Cjc 1295 and Sermorelin

Choosing between Cjc 1295 and Sermorelin depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.

Head-to-head clinical trial data between Cjc 1295 and Sermorelin is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.

Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.

Cjc 1295 vs Sermorelin: Common Questions

CJC-1295 (with or without DAC) is a growth hormone releasing hormone analogue while Sermorelin (GRF 1-29) is a growth hormone releasing hormone analogue. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.

Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.

CJC-1295 (with or without DAC) works as a growth hormone releasing hormone analogue (DAC: 2 mg/week SC; No-DAC: 100 mcg 2-3x daily), while Sermorelin (GRF 1-29) is a growth hormone releasing hormone analogue (200-500 mcg SC daily at bedtime). They have different half-lives (DAC: ~8 days; No-DAC: ~30 min vs ~10-20 minutes), side effect profiles, and levels of clinical evidence.

Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.

Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.

Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.

References

Track Cjc 1295 or Sermorelin in Shotlee

Free dose tracking, side effect logging, and outcome comparison for any medication protocol.

🚀 Use Shotlee for Free